Cargando…

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience

In randomized clinical trials (RCTs) proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors showed a favorable safety profile, however, “real‐world” data on adverse events (AEs) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and Vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gürgöze, Muhammed T., Muller‐Hansma, Annemarie H.G., Schreuder, Michelle M., Galema‐Boers, Annette M.H., Boersma, Eric, Roeters van Lennep, Jeanine E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704355/ https://www.ncbi.nlm.nih.gov/pubmed/30053327 http://dx.doi.org/10.1002/cpt.1193

Ejemplares similares

The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
por: Schreuder, Michelle M., et al.
Publicado: (2021)

Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors
por: Bots, Sophie H., et al.
Publicado: (2022)

Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy
por: Benschop, Laura, et al.
Publicado: (2019)

Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
por: Sleutjes, Jasmijn A. M., et al.
Publicado: (2021)

Efficacy and Safety of High Potent P2Y(12) Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex‐Specific Systematic Review and Meta‐Analysis
por: Schreuder, Michelle M., et al.
Publicado: (2020)

Integration of sex and gender in cardiovascular medicine: a scientific and clinical imperative
por: Kavousi, Maryam, et al.
Publicado: (2023)

Supraventricular tachycardia and the menstrual cycle
por: Schreuder, M.M., et al.
Publicado: (2019)

Catamenial chest pain and spontaneous coronary artery dissection: A case report
por: Al Fatly, Zainab, et al.
Publicado: (2020)

Effects of menstruation on the onset of acute coronary syndrome in premenopausal women: A case series
por: van der Bijl, Marte F., et al.
Publicado: (2023)

Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation
por: Sleutjes, Jasmijn A M, et al.
Publicado: (2022)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases
por: Al Dubayee, Mohammed, et al.
Publicado: (2022)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Aging, Cardiovascular Risk, and SHBG Levels in Men and Women From the General Population
por: Aribas, Elif, et al.
Publicado: (2021)

Sex Differences in Familial Hypercholesterolemia
por: Klevmoen, Marianne, et al.
Publicado: (2023)

Influence of chronic kidney disease and other risk factors pre-heart transplantation on malignancy incidence post-heart transplantation
por: Roest, Stefan, et al.
Publicado: (2023)

Systematic review with meta‐analysis: effect of inflammatory bowel disease therapy on lipid levels
por: Sleutjes, Jasmijn A. M., et al.
Publicado: (2021)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

Early Pregnancy Cardiovascular Health and Subclinical Atherosclerosis
por: Benschop, Laura, et al.
Publicado: (2019)

Real-world use of PCSK9 inhibitors: A single-center experience
por: Sarsam, Sinan, et al.
Publicado: (2018)

Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study
por: Ambrož, Martina, et al.
Publicado: (2021)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

Preventing cardiovascular disease after hypertensive disorders of pregnancy: Searching for the how and when
por: Groenhof, T Katrien J, et al.
Publicado: (2017)

Cardiac medication use in patients with suspected ischaemia without obstructive coronary arteries: sex differences and psychological distress
por: Mommersteeg, P. M. C., et al.
Publicado: (2021)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review
por: Houttu, Veera, et al.
Publicado: (2023)

Cardiovascular Risk Factors Track From Mother to Child
por: Benschop, Laura, et al.
Publicado: (2018)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study
por: Singh, Sunny S., et al.
Publicado: (2020)

Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health
por: Bergen, Nienke E., et al.
Publicado: (2018)

Maternal lipid profile in pregnancy and embryonic size: a population-based prospective cohort study
por: Gootjes, Dionne V., et al.
Publicado: (2022)

Sex steroids and sex steroid‐binding globulin levels amongst middle‐aged and elderly men and women from general population
por: Aribas, Elif, et al.
Publicado: (2022)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

The cardiovascular risk profile of middle‐aged women with polycystic ovary syndrome
por: Meun, Cindy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dr2trunod7lc5jkqn5bav3adjj